On February 19, 2026, LIXTE Biotechnology Holdings will underwrite the first Good Health: Mind, Body & Soul Summit at Morehouse College in Atlanta. The invitation-only gathering, inspired by De La Soul’s legacy and held in partnership with Blacksmith Holdings, will convene approximately 150 leaders in healthcare, culture, science and community advocacy to address health equity for Black men and families. Highlights include panel discussions on cancer prevention and treatment, heart disease management, mental health strategies, substance use recovery, sleep optimization and intergenerational wellness. Geordan Pursglove, LIXTE’s CEO, will showcase the company’s clinical‐stage PP2A inhibitor LB-100 and outline collaborative research through LIORA, the company’s European proton therapy subsidiary, emphasizing LIXTE’s commitment to bridging scientific innovation with underserved communities.

LIXTE Biotechnology will attend the DealFlow Discovery Conference on January 28–29, 2026, at The Borgata Hotel in Atlantic City, where CEO Geordan Pursglove is scheduled for one-on-one investor meetings. The company will highlight ongoing proof-of-concept trials of its first-in-class PP2A inhibitor LB-100 in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. LIXTE will also discuss its activation lethality approach, supported by a comprehensive patent portfolio, and progress in developing the LiGHT System proton therapy platform through its wholly owned subsidiary, Liora Technologies Europe Ltd. Attendees can register online to explore collaboration opportunities and review safety and efficacy data demonstrating LB-100’s anti-cancer activity at tolerated dose levels.